SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

Search

Laboratorios Farmaceuticos Rovi SA

Abrir

SetorSaúde

79.35 0.51

Visão Geral

Variação de preço das ações

24h

Atual

Mín

78.55

Máximo

79.75

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

33.602

60.328

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+7.5% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

79M

4.1B

Abertura anterior

78.84

Fecho anterior

79.35

Sentimento de Notícias

By Acuity

50%

50%

177 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de abr. de 2026, 23:33 UTC

Ações em Alta

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 de abr. de 2026, 23:24 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 de abr. de 2026, 22:46 UTC

Ganhos

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 de abr. de 2026, 22:37 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 de abr. de 2026, 22:15 UTC

Ganhos
Notícias Principais

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 de abr. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 de abr. de 2026, 23:19 UTC

Conversa de Mercado
Ganhos

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 de abr. de 2026, 23:09 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 de abr. de 2026, 23:03 UTC

Conversa de Mercado

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 de abr. de 2026, 22:51 UTC

Ganhos

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 de abr. de 2026, 22:40 UTC

Conversa de Mercado
Notícias Principais

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 de abr. de 2026, 22:32 UTC

Ganhos

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 de abr. de 2026, 22:22 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 de abr. de 2026, 22:17 UTC

Conversa de Mercado

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 de abr. de 2026, 22:07 UTC

Conversa de Mercado
Notícias Principais

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

7.5% parte superior

Previsão para 12 meses

Média 86.75 EUR  7.5%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

177 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat